Kidney transplant study tests vaccine booster strategy
NCT ID NCT05060991
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether temporarily reducing immunosuppressive medication can help kidney transplant recipients mount a stronger immune response to a third dose of the COVID-19 mRNA vaccine. Fourteen participants with low or no antibodies will have their antimetabolite dose lowered before and after vaccination. The goal is to see if this improves antibody levels while monitoring for organ rejection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
reduction in antimetabolite immunosuppression (mycophenolate mofetil/mycophenolic acid or azathioprine)
What this could lead to
If successful, this could point toward a way to improve vaccine protection for immunocompromised kidney transplant recipients.
What could go wrong
This is a very small early-phase study with only 14 participants, so results may not apply broadly. Lowering immunosuppression carries a risk of organ rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, Davis
Sacramento, California, 95817, United States